Kun for helsepersonell

Søk

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss

Menu

Close

Om ZaviceftaVirkningsmekanismePatogen dekningTidlig hensiktsmessig behandlingIDSA anbefalingØkonomiske holdepunkterSpørsmål og svar om ZAVICEFTAPasientprofilerHAP/VAP pasientcUTI pasientcIAI pasientPediatriske pasienterSpørsmål og svar - FAQsEffekt Real-world evidenceEffektdataSpørsmål og svar om effektSikkerhetSikkerhet hos voksneSikkerhet hos barn/ungdomSpørsmål og svar om sikkerhetDoseringDosering hos voksneDosering hos barn/ungdomSpørsmål og svar om dosering
Dosering hos voksne

Normal adult renal function

Adult renal impairment

Tab Number 3

ZAVICEFTA (ceftazidime–avibactam) has consistent dosing across indications, with no dosage adjustments required in the elderly, adult patients with mild renal impairment (estimated CrCl ≥ 51 to ≤80 mL/min) and those with hepatic impairment1

Recommended dose for adult patients with estimated CrCl ≥51 mL/min1*

Scroll left to view table

Dosage adjustment is required for patients with renal impairment (estimated CrCl ≤50 mL/min)1

Recommended dose adjustments in adult patients with estimated CrCl ≤50 mL/min:1

Scroll left to view table
Listen to Professor Federico Pea

From the Department Of Medical and Surgical Science, Alma Mater Studiorum, University of Bologna, Italy as he discusses PK/PD attributes of ZAVICEFTA in patients.

Explore moreSafety and tolerability

Learn more about ZAVICEFTA’s safety and tolerability in adult and paediatric patients.

Loading
Footnotes:*The dose of ZAVICEFTA in adult patients with estimated CrCl ≤50 mL/min should be adjusted according to recommended doses. CrCl estimated using the Cockcroft-Gault formula.1
To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.1
To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.1
§The total duration shown may include intravenous ZAVICEFTA followed by appropriate oral therapy.1
There is very limited experience with the use of ZAVICEFTA for more than 14 days.1
**CrCl estimated using the Cockcroft–Gault formula.1
††Dose recommendations are based on PK modelling.1
‡‡Dosing of ZAVICEFTA on haemodialysis days should occur after completion of haemodialysis.1
Abbreviations:cIAI, complicated intra-abdominal infection; CrCl, creatinine clearance; cUTI, complicated urinary tract infection; ESRD, end-stage renal disease; HAP, hospital-acquired pneumonia; PK, pharmacokinetic; VAP, ventilator-associated pneumonia.Reference:ZAVICEFTA SPC
Preparatomtale
PP-ZVA-NOR-0141 Mai 2023
Dosering

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 

Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei